EFS of 205 high-risk patients treated on DFCI ALL Consortium Protocol 95-01 (1996-2000) by randomized treatment group (doxorubicin given alone or with dexrazoxane). At a median follow-up of 8.7 years, EFS was 77% (95% confidence interval, 67-84) in the doxorubicin group, and 76% (95% confidence interval, 67-84) in the doxorubicin plus dexrazoxane group (P = .99). Adapted with permission from Lipshultz et al, 2010.¹⁴